001-4802 | 22-0760120 | |
(Commission File Number) | (IRS Employer Identification No.) |
1 Becton Drive, Franklin Lakes, New Jersey | 07417-1880 | |
(Address of Principal Executive Offices) | (Zip Code) |
| Revenues. We present international and total revenue growth rates (for the total company and each of its business segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods. | ||
| Earnings Per Share from Continuing Operations. We present our diluted earnings per share from continuing operations (EPS) for the second quarter and first six months of fiscal year 2010, and for the full fiscal year 2010, after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. This item is not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of EPS are more indicative of BDs underlying performance for these periods, and allow investors to better assess our EPS guidance for fiscal year 2011. We also present our EPS growth for the second quarter and first six months of fiscal year 2011, and our EPS guidance for the full 2011 fiscal year, after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to the prior year periods, and also allow investors to better understand BDs EPS guidance. |
Exhibit 99.1
|
Press release dated April 26, 2011, which is furnished pursuant to Item 2.02 |
BECTON, DICKINSON AND COMPANY (Registrant) |
||||
By: | /s/ Gary DcFazio | |||
Gary DcFazio | ||||
Vice President and Corporate Secretary | ||||
99.1
|
Press release dated April 26, 2011, which is furnished pursuant to Item 2.02 |
1
2
3
4
Three Months Ended March 31, | ||||||||||||
2011 | 2010 | % Change | ||||||||||
REVENUES |
$ | 1,922,023 | $ | 1,799,409 | 6.8 | |||||||
Cost of products sold |
920,589 | 864,492 | 6.5 | |||||||||
Selling and administrative |
441,942 | 421,076 | 5.0 | |||||||||
Research and development |
119,152 | 100,193 | 18.9 | |||||||||
TOTAL OPERATING COSTS
AND EXPENSES |
1,481,683 | 1,385,761 | 6.9 | |||||||||
OPERATING INCOME |
440,340 | 413,648 | 6.5 | |||||||||
Interest income |
14,564 | 9,652 | 50.9 | |||||||||
Interest expense |
(23,921 | ) | (12,913 | ) | 85.2 | |||||||
Other (expense) income, net |
(2,522 | ) | 164 | NM | ||||||||
INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES |
428,461 | 410,551 | 4.4 | |||||||||
Income tax provision |
117,399 | 125,517 | (6.5 | ) | ||||||||
INCOME FROM CONTINUING OPERATIONS |
311,062 | 285,034 | 9.1 | |||||||||
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$377 AND $4,101, RESPECTIVELY |
957 | 12,597 | (92.4 | ) | ||||||||
NET INCOME |
$ | 312,019 | $ | 297,631 | 4.8 | |||||||
EARNINGS PER SHARE |
||||||||||||
Basic: |
||||||||||||
Income from continuing operations |
$ | 1.41 | $ | 1.21 | 16.5 | |||||||
Income from discontinued operations |
$ | | $ | 0.05 | NM | |||||||
Net income |
$ | 1.41 | $ | 1.26 | 11.9 | |||||||
Diluted: |
||||||||||||
Income from continuing operations |
$ | 1.38 | $ | 1.18 | 16.9 | |||||||
Income from discontinued operations |
$ | | $ | 0.05 | NM | |||||||
Net income (1) |
$ | 1.38 | $ | 1.24 | 11.3 | |||||||
AVERAGE SHARES OUTSTANDING |
||||||||||||
Basic |
220,894 | 235,325 | ||||||||||
Diluted |
225,467 | 240,863 | ||||||||||
NM Not Meaningful | ||
(1) | Total per share amounts may not add due to rounding |
Page 1
Six Months Ended March 31, | ||||||||||||
2011 | 2010 | % Change | ||||||||||
REVENUES |
$ | 3,764,028 | $ | 3,668,227 | 2.6 | |||||||
Cost of products sold |
1,786,020 | 1,758,816 | 1.5 | |||||||||
Selling and administrative |
889,897 | 866,749 | 2.7 | |||||||||
Research and development |
234,693 | 199,344 | 17.7 | |||||||||
TOTAL OPERATING COSTS
AND EXPENSES |
2,910,610 | 2,824,909 | 3.0 | |||||||||
OPERATING INCOME |
853,418 | 843,318 | 1.2 | |||||||||
Interest income |
29,786 | 18,441 | 61.5 | |||||||||
Interest expense |
(39,474 | ) | (25,900 | ) | 52.4 | |||||||
Other expense, net |
(7,118 | ) | (2,190 | ) | NM | |||||||
INCOME FROM CONTINUING OPERATIONS BEFORE
INCOME TAXES |
836,612 | 833,669 | 0.4 | |||||||||
Income tax provision |
211,273 | 244,542 | (13.6 | ) | ||||||||
INCOME FROM CONTINUING OPERATIONS |
625,339 | 589,127 | 6.1 | |||||||||
INCOME FROM DISCONTINUED OPERATIONS
NET OF INCOME TAX PROVISION OF
$601 AND $8,718, RESPECTIVELY |
2,617 | 24,880 | (89.5 | ) | ||||||||
NET INCOME |
$ | 627,956 | $ | 614,007 | 2.3 | |||||||
EARNINGS PER SHARE |
||||||||||||
Basic: |
||||||||||||
Income from continuing operations |
$ | 2.79 | $ | 2.49 | 12.0 | |||||||
Income from discontinued operations |
$ | 0.01 | $ | 0.11 | (90.9 | ) | ||||||
Net income |
$ | 2.80 | $ | 2.60 | 7.7 | |||||||
Diluted: |
||||||||||||
Income from continuing operations |
$ | 2.72 | $ | 2.43 | 11.9 | |||||||
Income from discontinued operations |
$ | 0.01 | $ | 0.10 | (90.0 | ) | ||||||
Net income (1) |
$ | 2.74 | $ | 2.53 | 8.3 | |||||||
AVERAGE SHARES OUTSTANDING |
||||||||||||
Basic |
224,528 | 236,353 | ||||||||||
Diluted |
229,529 | 242,327 | ||||||||||
NM Not Meaningful | ||
(1) | Total per share amounts may not add due to rounding |
Page 2
Three Months Ended March 31, | ||||||||||||
2011 | 2010 | % Change | ||||||||||
BD MEDICAL |
||||||||||||
United States |
$ | 398,487 | $ | 381,767 | 4.4 | |||||||
International |
582,845 | 539,866 | 8.0 | |||||||||
TOTAL |
$ | 981,332 | $ | 921,633 | 6.5 | |||||||
BD DIAGNOSTICS |
||||||||||||
United States |
$ | 310,617 | $ | 292,841 | 6.1 | |||||||
International |
294,730 | 262,831 | 12.1 | |||||||||
TOTAL |
$ | 605,347 | $ | 555,672 | 8.9 | |||||||
BD BIOSCIENCES |
||||||||||||
United States |
$ | 120,077 | $ | 117,151 | 2.5 | |||||||
International |
215,267 | 204,953 | 5.0 | |||||||||
TOTAL |
$ | 335,344 | $ | 322,104 | 4.1 | |||||||
TOTAL REVENUES |
||||||||||||
United States |
$ | 829,181 | $ | 791,759 | 4.7 | |||||||
International |
1,092,842 | 1,007,650 | 8.5 | |||||||||
TOTAL |
$ | 1,922,023 | $ | 1,799,409 | 6.8 | |||||||
Page 3
Six Months Ended March 31, | ||||||||||||
2011 | 2010 | % Change | ||||||||||
BD MEDICAL |
||||||||||||
United States |
$ | 804,014 | $ | 814,344 | (1.3 | ) | ||||||
International |
1,103,863 | 1,077,959 | 2.4 | |||||||||
TOTAL |
$ | 1,907,877 | $ | 1,892,303 | 0.8 | |||||||
BD DIAGNOSTICS |
||||||||||||
United States |
$ | 619,467 | $ | 603,045 | 2.7 | |||||||
International |
587,603 | 548,102 | 7.2 | |||||||||
TOTAL |
$ | 1,207,070 | $ | 1,151,147 | 4.9 | |||||||
BD BIOSCIENCES |
||||||||||||
United States |
$ | 234,302 | $ | 227,787 | 2.9 | |||||||
International |
414,779 | 396,990 | 4.5 | |||||||||
TOTAL |
$ | 649,081 | $ | 624,777 | 3.9 | |||||||
TOTAL REVENUES |
||||||||||||
United States |
$ | 1,657,783 | $ | 1,645,176 | 0.8 | |||||||
International |
2,106,245 | 2,023,051 | 4.1 | |||||||||
TOTAL |
$ | 3,764,028 | $ | 3,668,227 | 2.6 | |||||||
Page 4
United States | ||||||||||||
2011 | 2010 | % Change | ||||||||||
BD MEDICAL |
||||||||||||
Medical Surgical Systems |
$ | 234,571 | $ | 237,174 | (1.1 | ) | ||||||
Diabetes Care |
95,939 | 92,515 | 3.7 | |||||||||
Pharmaceutical Systems |
67,977 | 52,078 | 30.5 | |||||||||
TOTAL |
$ | 398,487 | $ | 381,767 | 4.4 | |||||||
BD DIAGNOSTICS |
||||||||||||
Preanalytical Systems |
$ | 156,978 | $ | 149,932 | 4.7 | |||||||
Diagnostic Systems |
153,639 | 142,909 | 7.5 | |||||||||
TOTAL |
$ | 310,617 | $ | 292,841 | 6.1 | |||||||
BD BIOSCIENCES |
||||||||||||
Cell Analysis |
$ | 83,006 | $ | 78,183 | 6.2 | |||||||
Discovery Labware |
37,071 | 38,968 | (4.9 | ) | ||||||||
TOTAL |
$ | 120,077 | $ | 117,151 | 2.5 | |||||||
TOTAL UNITED STATES |
$ | 829,181 | $ | 791,759 | 4.7 | |||||||
Page 5
International | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
BD MEDICAL |
||||||||||||||||||||
Medical Surgical Systems |
$ | 270,020 | $ | 244,090 | 10.6 | 5.7 | 4.9 | |||||||||||||
Diabetes Care |
111,820 | $ | 95,471 | 17.1 | 12.4 | 4.7 | ||||||||||||||
Pharmaceutical Systems |
201,005 | $ | 200,305 | 0.3 | 1.2 | (0.9 | ) | |||||||||||||
TOTAL |
$ | 582,845 | $ | 539,866 | 8.0 | 5.3 | 2.7 | |||||||||||||
BD DIAGNOSTICS |
||||||||||||||||||||
Preanalytical Systems |
$ | 149,261 | $ | 137,738 | 8.4 | 3.9 | 4.5 | |||||||||||||
Diagnostic Systems |
145,469 | 125,093 | 16.3 | 10.7 | 5.6 | |||||||||||||||
TOTAL |
$ | 294,730 | $ | 262,831 | 12.1 | 7.1 | 5.0 | |||||||||||||
BD BIOSCIENCES |
||||||||||||||||||||
Cell Analysis |
$ | 172,510 | $ | 164,292 | 5.0 | (0.5 | ) | 5.5 | ||||||||||||
Discovery Labware |
42,757 | 40,661 | 5.2 | (1.6 | ) | 6.8 | ||||||||||||||
TOTAL |
$ | 215,267 | $ | 204,953 | 5.0 | (0.8 | ) | 5.8 | ||||||||||||
TOTAL INTERNATIONAL |
$ | 1,092,842 | $ | 1,007,650 | 8.5 | 4.6 | 3.9 | |||||||||||||
Page 6
Total | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
BD MEDICAL |
||||||||||||||||||||
Medical Surgical Systems |
$ | 504,591 | $ | 481,264 | 4.8 | 2.3 | 2.5 | |||||||||||||
Diabetes Care |
207,759 | 187,986 | 10.5 | 8.1 | 2.4 | |||||||||||||||
Pharmaceutical Systems |
268,982 | 252,383 | 6.6 | 7.3 | (0.7 | ) | ||||||||||||||
TOTAL |
$ | 981,332 | $ | 921,633 | 6.5 | 4.9 | 1.6 | |||||||||||||
BD DIAGNOSTICS |
||||||||||||||||||||
Preanalytical Systems |
$ | 306,239 | $ | 287,670 | 6.5 | 4.4 | 2.1 | |||||||||||||
Diagnostic Systems |
299,108 | 268,002 | 11.6 | 9.0 | 2.6 | |||||||||||||||
TOTAL |
$ | 605,347 | $ | 555,672 | 8.9 | 6.5 | 2.4 | |||||||||||||
BD BIOSCIENCES |
||||||||||||||||||||
Cell Analysis |
$ | 255,516 | $ | 242,475 | 5.4 | 1.7 | 3.7 | |||||||||||||
Discovery Labware |
79,828 | 79,629 | 0.2 | (3.3 | ) | 3.5 | ||||||||||||||
TOTAL |
$ | 335,344 | $ | 322,104 | 4.1 | 0.4 | 3.7 | |||||||||||||
TOTAL REVENUES |
$ | 1,922,023 | $ | 1,799,409 | 6.8 | 4.6 | 2.2 | |||||||||||||
Page 7
United States | ||||||||||||
2011 | 2010 | % Change | ||||||||||
BD MEDICAL |
||||||||||||
Medical Surgical Systems |
$ | 488,825 | $ | 511,166 | (4.4 | ) | ||||||
Diabetes Care |
195,524 | 189,079 | 3.4 | |||||||||
Pharmaceutical Systems |
119,665 | 114,099 | 4.9 | |||||||||
TOTAL |
$ | 804,014 | $ | 814,344 | (1.3 | ) | ||||||
BD DIAGNOSTICS |
||||||||||||
Preanalytical Systems |
$ | 319,036 | $ | 306,167 | 4.2 | |||||||
Diagnostic Systems |
300,431 | 296,878 | 1.2 | |||||||||
TOTAL |
$ | 619,467 | $ | 603,045 | 2.7 | |||||||
BD BIOSCIENCES |
||||||||||||
Cell Analysis |
$ | 163,262 | $ | 155,787 | 4.8 | |||||||
Discovery Labware |
71,040 | 72,000 | (1.3 | ) | ||||||||
TOTAL |
$ | 234,302 | $ | 227,787 | 2.9 | |||||||
TOTAL UNITED STATES |
$ | 1,657,783 | $ | 1,645,176 | 0.8 | |||||||
Page 8
International | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
BD MEDICAL |
||||||||||||||||||||
Medical Surgical Systems |
$ | 528,491 | $ | 503,273 | 5.0 | 1.7 | 3.3 | |||||||||||||
Diabetes Care |
226,118 | 200,428 | 12.8 | 10.5 | 2.3 | |||||||||||||||
Pharmaceutical Systems |
349,254 | 374,258 | (6.7 | ) | (4.4 | ) | (2.3 | ) | ||||||||||||
TOTAL |
$ | 1,103,863 | $ | 1,077,959 | 2.4 | 1.2 | 1.2 | |||||||||||||
BD DIAGNOSTICS |
||||||||||||||||||||
Preanalytical Systems |
$ | 299,832 | $ | 281,670 | 6.4 | 3.9 | 2.5 | |||||||||||||
Diagnostic Systems |
287,771 | 266,432 | 8.0 | 4.8 | 3.2 | |||||||||||||||
TOTAL |
$ | 587,603 | $ | 548,102 | 7.2 | 4.4 | 2.8 | |||||||||||||
BD BIOSCIENCES |
||||||||||||||||||||
Cell Analysis |
$ | 332,997 | $ | 318,025 | 4.7 | 1.9 | 2.8 | |||||||||||||
Discovery Labware |
81,782 | 78,965 | 3.6 | (0.9 | ) | 4.5 | ||||||||||||||
TOTAL |
$ | 414,779 | $ | 396,990 | 4.5 | 1.4 | 3.1 | |||||||||||||
TOTAL INTERNATIONAL |
$ | 2,106,245 | $ | 2,023,051 | 4.1 | 2.1 | 2.0 | |||||||||||||
Page 9
Total | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
BD MEDICAL |
||||||||||||||||||||
Medical Surgical Systems |
$ | 1,017,316 | $ | 1,014,439 | 0.3 | (1.4 | ) | 1.7 | ||||||||||||
Diabetes Care |
421,642 | 389,507 | 8.3 | 7.1 | 1.2 | |||||||||||||||
Pharmaceutical Systems |
468,919 | 488,357 | (4.0 | ) | (2.2 | ) | (1.8 | ) | ||||||||||||
TOTAL |
$ | 1,907,877 | $ | 1,892,303 | 0.8 | 0.1 | 0.7 | |||||||||||||
BD DIAGNOSTICS |
||||||||||||||||||||
Preanalytical Systems |
$ | 618,868 | $ | 587,837 | 5.3 | 4.1 | 1.2 | |||||||||||||
Diagnostic Systems |
588,202 | 563,310 | 4.4 | 2.9 | 1.5 | |||||||||||||||
TOTAL |
$ | 1,207,070 | $ | 1,151,147 | 4.9 | 3.6 | 1.3 | |||||||||||||
BD BIOSCIENCES |
||||||||||||||||||||
Cell Analysis |
$ | 496,259 | $ | 473,812 | 4.7 | 2.8 | 1.9 | |||||||||||||
Discovery Labware |
152,822 | 150,965 | 1.2 | (1.1 | ) | 2.3 | ||||||||||||||
TOTAL |
$ | 649,081 | $ | 624,777 | 3.9 | 1.9 | 2.0 | |||||||||||||
TOTAL REVENUES |
$ | 3,764,028 | $ | 3,668,227 | 2.6 | 1.5 | 1.1 | |||||||||||||
Page 10
Three Months Ended March 31, | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
TOTAL SAFETY REVENUES |
||||||||||||||||||||
United States |
$ | 263,524 | $ | 263,044 | 0.2 | 0.2 | | |||||||||||||
International |
177,859 | 148,537 | 19.7 | 14.1 | 5.6 | |||||||||||||||
TOTAL |
$ | 441,383 | $ | 411,581 | 7.2 | 5.2 | 2.0 | |||||||||||||
BY SEGMENT |
||||||||||||||||||||
BD Medical |
$ | 204,866 | $ | 193,688 | 5.8 | 3.9 | 1.9 | |||||||||||||
BD Diagnostics |
236,517 | 217,893 | 8.5 | 6.3 | 2.2 | |||||||||||||||
TOTAL |
$ | 441,383 | $ | 411,581 | 7.2 | 5.2 | 2.0 | |||||||||||||
Six Months Ended March 31, | ||||||||||||||||||||
% Change | ||||||||||||||||||||
2011 | 2010 | Reported | FXN | FX Impact | ||||||||||||||||
TOTAL SAFETY REVENUES |
||||||||||||||||||||
United States |
$ | 547,306 | $ | 554,859 | (1.4 | ) | (1.4 | ) | | |||||||||||
International |
347,113 | 303,666 | 14.3 | 10.8 | 3.5 | |||||||||||||||
TOTAL |
$ | 894,419 | $ | 858,525 | 4.2 | 2.9 | 1.3 | |||||||||||||
BY SEGMENT |
||||||||||||||||||||
BD Medical |
$ | 418,175 | $ | 414,862 | 0.8 | (0.4 | ) | 1.2 | ||||||||||||
BD Diagnostics |
476,244 | 443,663 | 7.3 | 6.0 | 1.3 | |||||||||||||||
TOTAL |
$ | 894,419 | $ | 858,525 | 4.2 | 2.9 | 1.3 | |||||||||||||
Page 11
Three Months Ended March 31, | ||||||||||||||||||||
Reported | Reported | Adjusted | Adjusted | |||||||||||||||||
FY 2011 | FY 2010 | Tax (1) | FY 2010 | % Growth | ||||||||||||||||
Diluted Earnings per Share from Continuing Operations |
$ | 1.38 | $ | 1.18 | $ | .04 | $ | 1.22 | 13.1 | % |
(1) | Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements. |
Page 12
Six Months Ended March 31, | ||||||||||||||||||||
Reported | Reported | Adjusted | Adjusted | |||||||||||||||||
FY 2011 | FY 2010 | Tax (1) | FY 2010 | % Growth | ||||||||||||||||
Diluted Earnings per Share
from Continuing Operations |
$ | 2.72 | $ | 2.43 | $ | .04 | $ | 2.47 | 10.1 | % |
(1) | Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements. |
Three Months Ended March 31, | ||||||||||||||||||||||||||||||||
Adjusted | Foreign | FY10 | Adjusted | |||||||||||||||||||||||||||||
Reported | Adjusted | Growth | Currency | Hedge | Total | FXN | FXN | |||||||||||||||||||||||||
FY 2011 | FY 2010 | $ | Translation | Loss | FX | Change | Growth | |||||||||||||||||||||||||
REVENUES |
$ | 1,922 | 1,799 | 123 | 13 | 27 | 40 | 83 | 4.6 | % | ||||||||||||||||||||||
Diluted Earnings per Share
from Continuing Operations |
$ | 1.38 | 1.22 | 0.16 | (0.00 | ) | 0.07 | 0.07 | 0.09 | 7.4 | % |
Six Months Ended March 31, | ||||||||||||||||||||||||||||||||
Adjusted | Foreign | FY10 | Adjusted | |||||||||||||||||||||||||||||
Reported | Adjusted | Growth | Currency | Hedge | Total | FXN | FXN | |||||||||||||||||||||||||
FY 2011 | FY 2010 | $ | Translation | Loss | FX | Change | Growth | |||||||||||||||||||||||||
REVENUES |
$ | 3,764 | 3,668 | 96 | (1 | ) | 41 | 41 | 55 | 1.5 | % | |||||||||||||||||||||
Diluted Earnings per Share
from Continuing Operations |
$ | 2.72 | 2.47 | 0.25 | 0.01 | 0.11 | 0.12 | 0.13 | 5.3 | % |
Reported Diluted Earnings per Share
from Continuing Operations |
$ | 4.90 | ||
Tax (1) |
0.04 | |||
Adjusted Diluted Earnings per Share
from Continuing Operations |
$ | 4.94 | ||
(1) | Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements. |
$A`-P&"`!0F2)@2]I=`7 Q:
MQ!B0,(@T;/\!"-4J@Q?H-@0$;"`-,""!X6:P`@U@+PL08-P0.$"#$"`!"&,8
M0#^:``,X6`4$6R#"`QJAN1ZX@'8WT,, ,021*`*#C"`"$B0@QNZP`4(@$,*8/`$
M9](`9*WL5XJ^2( 4!T!;"'.:!`!//R
M0`JHB2X/1``!6PB!&F23`P,TK0QIT"SK!I"#P-K2`<5R@!JND(9%:.`*XQ,!
M#TK@"`L8`&L]4<,&"D&"X@D`'6FX@@`$8``>Y$!O!IA7(P,(`Z%\Y0\J6($%
M?-"&.$0A`FB3CPIR``,_&!@"C&B"&L803#_0(`?3$\$U<.R"UJY.OD!6UAL`
M:HD'&%D^M6&6)&P4H61(@*4$)&"`!4+C$#\IX@WL8L0#WB"D('M95@_I5(0H
M(>9&^``">KC!$EZ0V<-TBI5?CK-2/;`!%I@`!/F2LY[WW!!%V">>:SH`?=
?"%$IB]"(1G2)%A3H1#O:RPL)DK`>36G-1AK(@0``.S\_
`
end
%ND1!$+2V*H
M:#RG3?\)""I\E+A,H\B#-JH9*